You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
128个药品纳入拟谈判准入范围福森药业、石药集团领涨药品股
格隆汇 08-21 11:54
格隆汇8月21日丨港股市场药品股普涨,其中,福森药业(1652.HK)涨9%,石药集团(1093.HK)和中生制药(1177.HK)涨超6%,石四药集团涨超5%,国药控股、中国先锋医药和三生制药涨超3%。在国家医保局召开的媒体吹风会上,初步确定将128个药品纳入拟谈判准入范围,包括109个西药和19个中成药。这些药品的治疗领域主要涉及癌症、罕见病等重大疾病、丙肝、乙肝以及高血压、糖尿病等慢性病等。注:康臣药业(1681.HK)今日官宣:益肾化湿颗粒和右旋糖酐铁口服溶液首次进入《2019版国家医保目录》。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account